Summit TherapeuticsSMMT
Market Cap: $8.89B
About: Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Employees: 105
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
170% more capital invested
Capital invested by funds: $208M [Q1] → $563M (+$355M) [Q2]
74% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 23
53% more call options, than puts
Call options by funds: $13.8M | Put options by funds: $9.02M
16% more funds holding
Funds holding: 104 [Q1] → 121 (+17) [Q2]
3.12% more ownership
Funds ownership: 7.17% [Q1] → 10.28% (+3.12%) [Q2]
57% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 47
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
HC Wainwright & Co. Mitchell Kapoor 49% 1-year accuracy 58 / 119 met price target | 30%upside $16 | Buy Reiterated | 3 Sept 2024 |
HC Wainwright & Co. Mitchell Kapoor 49% 1-year accuracy 58 / 119 met price target | 30%upside $16 | Buy Reiterated | 21 Aug 2024 |
HC Wainwright & Co. Mitchell Kapoor 49% 1-year accuracy 58 / 119 met price target | 30%upside $16 | Buy Reiterated | 15 Aug 2024 |
HC Wainwright & Co. Mitchell Kapoor 49% 1-year accuracy 58 / 119 met price target | 30%upside $16 | Buy Reiterated | 14 Aug 2024 |
HC Wainwright & Co. Mitchell Kapoor 49% 1-year accuracy 58 / 119 met price target | 30%upside $16 | Buy Initiated | 12 Aug 2024 |
Financial journalist opinion
Based on 5 articles about SMMT published over the past 30 days